BriaCell Therapeutics
(NASDAQ) BCTX
BriaCell Therapeutics Financials at a Glance
Market Cap
$32.77M
Revenue (TTM)
$0.00
Net Income (TTM)
$38.37M
EPS (TTM)
$-27.63
P/E Ratio
-0.16
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$4.35
Volume
546
Open
$4.40
Price
$4.35
Volume
546
Open
$4.40
Previous Close
$4.52
Daily Range
$4.35 - $4.40
52-Week Range
$3.60 - $98.20
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$4.35
Volume
546
Open
$4.40
Previous Close
$4.52
Daily Range
$4.35 - $4.40
52-Week Range
$3.60 - $98.20
BCTX News
BCTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BriaCell Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
17
CEO
William V. Williams, MD
Website
www.briacell.comHeadquarters
West Vancouver, BC V7T 2X1, CA
BCTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-172%
Return on Capital
-97%
Return on Assets
-1%
Earnings Yield
-6.25%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$32.77M
Shares Outstanding
7.25M
Volume
546
Short Interest
0.00%
Avg. Volume
495.04K
Financials (TTM)
Gross Profit
$147.89K
Operating Income
$37.73M
EBITDA
$36.63M
Operating Cash Flow
$39.07M
Capital Expenditure
$3.08
Free Cash Flow
$39.07M
Cash & ST Invst.
$24.56M
Total Debt
$0.00
BriaCell Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$37.04K
+3.5%
Gross Margin
0.00%
N/A
Market Cap
$32.77M
N/A
Market Cap/Employee
$2.05M
N/A
Employees
16
N/A
Net Income
$7.22M
+20.3%
EBITDA
$10.43M
-14.7%
Quarterly Fundamentals
Net Cash
$29.90M
+304.7%
Accounts Receivable
$3.09M
-2.6%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-1.01%
N/A
Return on Invested Capital
-97.34%
N/A
Free Cash Flow
$4.98M
+41.7%
Operating Cash Flow
$4.98M
+41.7%